Impact of polycystic ovary, metabolic syndrome and obesity on women health . Volume 8 Frontiers in gynecological endocrinology / / Andrea R. Genazzani [and three others], editors

• Pubblicazione: Cham, Switzerland : , : Springer, , [2021]; ©2021
• Descrizione fisica: 1 online resource (227 pages)
• Disciplina: 618.11
• Soggetto topico: Polycystic ovary syndrome; Metabolic syndrome; Obesity; Malalties de l'ovari; Quistos; Síndrome metabòlica; Obesitat; Ginecologia endocrina
• Soggetto genere / forma: Llibres electrònics
• Persona (resp. second.): GenazzaniAndrea R.
• Nota di contenuto: Intro -- Preface -- Contents -- 1: The Brain Phenotype in Polycystic Ovary Syndrome (PCOS): Androgens, Anovulation, and Gender -- 1.1 Introduction -- 1.2 Anovulation Reflects the PCOS Brain Phenotype -- 1.3 Neuroregulation of GnRH and the Brain Phenotype in PCOS -- 1.4 Gender Identity and Sexual Orientation -- 1.5 Summary -- References -- 2: Adolescence: A High-Risk Period for PCOS Development? -- 2.1 The Role of Peri-Pubertal Obesity -- 2.2 Hyperandrogenism -- 2.3 GnRH Dysregulation -- 2.4 Brain Disorders -- 2.5 Endocrine-Disrupting Chemicals -- 2.6 Gut Microbiota -- 2.7 AMH -- 2.8 Conclusions -- References -- 3: Toward Adolescent Prevention of Adult Anovulation in Polycystic Ovary Syndrome -- 3.1 Definition, Origins, and Diagnosis of Adolescent PCOS -- 3.2 Treatment of Adolescent PCOS: Lifestyle, Estro-Progestagen, SPIOMET -- 3.3 SPIOMET Experience in Adolescent Girls: Limited but Promising -- 3.4 Perspective -- References -- 4: Environmental Factors Responsible for Obesity and Insulin Resistance in Polycystic Ovary Syndrome -- 4.1 Endocrine-Disrupting Chemicals -- 4.1.1 Bisphenol A -- 4.2 Advanced Glycation End Products -- 4.2.1 Vitamin D -- References -- 5: Pathogenesis of PCOS: From Metabolic and Neuroendocrine Implications to the Choice of the Therapeutic Strategy -- 5.1 Introduction -- 5.2 Physiopathology of the PCOS Patients -- 5.2.1 Weight and Metabolism -- 5.2.2 Hyperandrogenism -- 5.2.3 Insulin Resistance -- 5.3 New Perspectives in the Pathogenesis of PCOS -- 5.4 Genetics, Metabolism, and PCOS -- 5.5 The Management of Infertility in PCOS Patients -- 5.5.1 Lifestyle Modification -- 5.5.2 Bariatric Surgery -- 5.5.3 Metformin -- 5.5.4 Clomiphene Citrate -- 5.5.5 Letrozole -- 5.5.6 Ovarian Drilling -- 5.5.7 Gonadotropins and IVF -- 5.5.8 Inositols -- 5.5.9 Alpha-Lipoic Acid -- 5.6 Conclusions. ; References -- 6: Polycystic Ovary Syndrome: Considerations About Therapeutic Strategies Choices from Fertile Life to Menopause -- 6.1 Introduction -- 6.2 Endocrine Profile of PCOS -- 6.3 Insulin Resistance (IR) and Compensatory Hyperinsulinism -- 6.4 How to Manage and What to Do in PCOS? -- 6.5 Estrogen-Progestin Preparations and PCOS -- 6.6 No Contraception but Let's Overcome Dysmetabolism! -- 6.7 Long-Term Consideration for PCOS! -- References -- 7: Impact of Polycystic Ovary Syndrome, Metabolic Syndrome, Obesity, and Follicular Growth Arrest in Women Health -- 7.1 Introduction -- 7.2 PCOS and Metabolic Syndrome Linkage -- 7.2.1 Insulin Resistance and Hyperinsulinism in PCOS -- 7.2.2 Role of Adipose Tissue in Insulin Resistance in PCOS -- 7.2.3 Role of Androgen in Insulin Resistance -- 7.3 Metabolic Syndrome, Hyperandrogenism, and Follicular Growth Arrest in PCOS -- 7.4 Intraovarian Mechanism of Follicular Growth Arrest in PCOS -- 7.5 Anti-Müllerian Hormone (AMH) and Follicular Growth Arrest -- 7.6 Dysregulation of Ovarian Angiogenesis and Estrogen Metabolites in the Follicular Growth Arrest -- 7.7 Conclusions -- References -- 8: Quality of Life and Sexual Health -- 8.1 Quality of Life -- 8.1.1 Hirsutism and Acne -- 8.1.2 Body Weight -- 8.1.3 Menstruation -- 8.1.4 Infertility -- 8.1.5 Psychological Distress (Depression and Anxiety) -- 8.2 Sexual Health -- 8.2.1 Impact of PCOS Traits on Sexual Function -- 8.2.2 General Impact of PCOS on Sexual Function -- 8.2.3 Androgens and Sexual Function in PCOS -- 8.3 Conclusions -- References -- 9: Infertility Management in Lean Versus Obese PCOS -- 9.1 Introduction -- 9.2 Pathophysiology of PCOS -- 9.2.1 Insulin Resistance and Hyperandrogenaemia -- 9.2.2 Obesity and Fertility -- 9.2.3 Obesity and Ovulatory Dysfunction -- 9.2.4 Lean Phenotype and Fertility. ; 9.2.5 Effect on Oocytes and Embryos -- 9.2.6 Effect on Endometrium -- 9.3 Management of Infertility -- 9.3.1 Lifestyle Modification in Obese PCOS -- 9.3.2 Lifestyle Modification in Lean PCOS -- 9.3.3 Bariatric Surgery -- 9.3.4 Anti-Obesity Drugs -- 9.4 Oral Contraceptive Pills (OCP) [31] -- 9.5 Ovulation Induction -- 9.5.1 Oral Ovulation Inducing Agents -- 9.5.2 Gonadotropins -- 9.5.3 GnRH Analogues -- 9.6 Laparoscopic Ovarian Drilling (LOD) -- 9.7 Assisted Reproductive Technologies (ART) -- 9.8 Insulin Sensitizers -- 9.8.1 Metformin -- 9.8.2 Inositols -- 9.8.3 Other Adjuvants -- 9.9 Psychological Intervention -- 9.9.1 Difference in Results between Obese and Lean PCOS -- 9.10 Preventing Complications -- 9.11 Conclusion -- References -- 10: Polycystic Ovary Syndrome: Fertility Treatment Options -- 10.1 Introduction -- 10.2 Fertility Treatment Options -- 10.2.1 Lifestyle Change for Weight Loss -- 10.2.2 Pharmacological and Surgical Ovulation Induction -- 10.2.2.1 Letrozole -- 10.2.2.2 Clomiphene Citrate -- 10.2.2.3 Metformin -- 10.2.2.4 Gonadotropins -- 10.2.2.5 Assisted Reproduction Technology -- 10.2.2.6 Ovarian Drilling -- 10.2.3 Other Treatment Options to Enhance Fertility -- 10.3 Selecting the Optimal Fertility Treatment Option -- 10.4 Conclusions -- References -- 11: Management of PCOS Women Preparing Pregnancy -- 11.1 Introduction -- 11.2 Pathophysiology of PCOS -- 11.3 Long-Term Consequences of PCOS -- 11.4 Treatment Targets -- 11.4.1 Lifestyle -- 11.4.2 Hyperandrogenism -- 11.4.3 Identifying Treatment Priorities in PCOS -- 11.4.4 Obesity -- 11.5 Insulin Resistance and Diabetes Mellitus -- 11.5.1 Decreased Fertility, Adverse Pregnancy Outcomes -- 11.6 Conclusion -- References -- 12: Impact of Polycystic Ovarian Syndrome, Metabolic Syndrome, and Obesity on Women's Health -- 12.1 Introduction. ; 12.2 Polycystic Ovarian Syndrome (PCOS) and Women's Health -- 12.2.1 PCOS and Fertility -- 12.2.2 PCOS and CVD Risk -- 12.2.3 PCOS and Depression -- 12.2.4 PCOS and Cancer Risk -- 12.3 Metabolic Syndrome (MetS) and Women's Health -- 12.3.1 MetS and Fertility -- 12.3.2 MetS and CVD Risk -- 12.3.3 MetS and Depression -- 12.4 Obesity: The Key Common Denominator in Women's Health -- 12.4.1 Obesity and Fertility -- 12.4.2 Obesity and Pregnancy -- 12.4.3 Obesity and Cancer Risk -- References -- 13: Pregnancy Outcome and Metabolic Syndrome -- 13.1 Introduction -- 13.2 Metabolic Syndrome, Obesity, and Pregnancy Complications -- 13.3 Inflammation, Insulin Resistance, and Oxidative Stress -- 13.4 Prevention of Adverse Obstetric Complications -- References -- 14: The Role of Insulin Resistance in Benign Breast Disease -- 14.1 Principles of Breast Endocrinology -- 14.2 Insulin -- 14.3 Benign Breast Disease -- 14.4 Benign Breast Disease and Breast Carcinoma -- 14.5 Conclusion -- References -- 15: Polycystic Ovary Syndrome and Inflammation -- 15.1 Introduction -- 15.2 Obesity and the PCOS -- 15.3 Inflammation and PCOS -- 15.3.1 Inflammation during Reproductive Life -- 15.3.2 Inflammation in Postmenopausal PCOS Women -- 15.4 Effect of Diet and Exercise on Inflammation -- 15.5 Effect of Probiotic and Synbiotic on Inflammation -- 15.6 Effect of Soy on Inflammation -- 15.7 Vitamin D Supplementation -- 15.8 Effect of Mineral Supplementation on Inflammation -- 15.9 Coenzyme Q10 Supplementation -- 15.10 Final Remarks -- References -- 16: Metabolic Changes at the Menopausal Transition -- 16.1 Introduction -- 16.2 Fat Distribution, Obesity, and Metabolic Syndrome (MS) -- 16.3 Relationship between Obesity, MS, and Menopausal Transition -- 16.3.1 Lipid Metabolism and Menopausal Transition. ; 16.3.2 The Management of Obesity and MS during Perimenopause -- 16.3.3 How to Prevent Weight Gain -- 16.4 Cardiovascular Disease and Menopause -- 16.5 Conclusions -- References -- 17: Cardiovascular Impact of Metabolic Abnormalities -- 17.1 Introduction -- 17.2 Lipids and Lipoproteins: What Happens in Menopause -- 17.3 Lipids and Lipoproteins: Effect of HRT on Lipids -- 17.4 Glucose: What Happens in Menopause -- 17.5 Glucose: Effect of HRT on Glucose -- 17.5.1 Hypertension: What Happens in Menopause -- 17.5.2 Hypertension: Effect of HRT on Hypertension -- 17.5.3 Obesity: What Happens in Menopause -- 17.5.4 Obesity: Effect on HRT on Weight -- 17.5.5 Inflammatory Markers: What Happens in Menopause -- 17.5.6 Inflammatory Markers: Effect of HRT on Inflammatory Markers -- 17.5.7 Vascular Function/VTE: What Happens in Menopause -- 17.6 Vascular Function/VTE: Effect of HRT on Vascular Function -- 17.7 Conclusion -- References -- 18: How to Prevent, Diagnose, and Treat Gynecological Cancer in PCO Patients? -- 18.1 Introduction -- 18.2 Endometrial Cancer Overview -- 18.3 Etiological and Molecular Mechanisms -- 18.4 Prevention of Endometrial Cancer -- 18.5 Place of Hormonal Prevention -- 18.5.1 Place of Weight Control -- 18.5.2 Place of Metformin -- 18.6 Diagnosis of Endometrial Hyperplasia and Cancer -- 18.7 Risk of Progression of Endometrial Hyperplasia -- 18.8 Treatment of Endometrial Hyperplasia and Cancer -- 18.8.1 Endometrial Hyperplasia -- 18.8.2 Endometrial Cancer -- 18.9 Conclusion -- References.
• Titolo autorizzato: Impact of polycystic ovary, metabolic syndrome and obesity on women health
• ISBN: 3-030-63650-X
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910506384103321
• Lo trovi qui: Univ. Federico II
• Serie: ISGE series.